'Prevention plus vaccination is what is going to take us into better territory by September or October.'
More vaccination would have been done in India if the State had not had complete control of all vaccination, notes Ajay Shah.
Like the UK variant identified earlier, the new variant of the novel coronavirus is also driving a massive resurgence of the disease in South Africa, with experts warning the country is probably facing a much larger second wave.
The Delta variant of COVID-19, or the B1.617.2 variant of concern (VOC) first identified in India, is about 60 per cent more transmissible than the Alpha strain identified in the United Kingdom and also reduces the effectiveness of vaccines to some extent, UK health experts report.
According to sources, around 10 crore doses of the Sputnik V vaccine is likely to be imported for emergency use in the country in the next six to seven months.
The international team of researchers combined lab-based experiments and epidemiology of vaccine breakthrough infections, showing that the Delta variant is better at replicating and spreading than other commonly-observed variants.
Prime Minister Narendra Modi's announcement of providing free inoculation to all adults will entail total spending of anywhere between Rs 45,000 crore and Rs 50,000 crore. This is higher than Rs 35,000 crore that the government had budgeted.
The Pune-based company's chief executive Adar Poonawalla said the company, which is the largest vaccine maker in the world, is putting $200 million at risk by manufacturing nearly 300 million doses before the final nod to launch the vaccine in market, which is expected at best by the end of the year.
Doses of the vaccine were given to 1,077 healthy adults aged between 18 and 55 in five United Kingdom hospitals in April and May as part of the phase one clinical trial.
Communications between the USTR and the world's most powerful pharmaceutical and trade lobbying groups reveal that many raised concerns about India's push to exempt Covid vaccines from intellectual property.
US President Joe Biden on Wednesday announced that the US will allocate 75 per cent - nearly 1.9 crore of the first tranche of 2.5 crore doses - of unused COVID-19 vaccines from its stockpile through the UN-backed COVAX global vaccine sharing programme to countries in South and Southeast Asia as well as Africa.
500 million doses per annum from its two sites in Hyderabad and 200 million doses each from its Ankleshwar and Kolar facilities.
So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.
The Department of Health and Social Care said a total of 81,959,398 doses of COVID vaccines have been administered in the UK, with 46,227,101 people receiving a first dose (87.8 per cent) and 35,732,297 people receiving both doses (67.8 per cent).
British nationals arriving in India, irrespective of their vaccination status, will have to undergo 10 days of mandatory quarantine from October 4 as part of the reciprocal actions initiated by the government following the vaccine certification row between the two countries.
According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its last meeting held on August 22.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS in New Delhi on Thursday, with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
IOC chief said he believed more than 80 per cent of residents of the Olympic Village would be vaccinated or booked for vaccination ahead of the Games
Prime Minister Narendra Modi said on Wednesday that international travel should be made easier through mutual recognition of vaccine certificates, amid several countries adopting different sets of rules to allow foreigners to enter their territory in the wake of the COVID-19 pandemic.
Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.
Once the UK drug regulator gives its approval to the Oxford vaccine, the expert committee on COVID-19 at the Central Drugs Standard Control Organisation (CDSCO) will hold its meeting and thoroughly review the safety and immunogenicity data from the clinical evaluations conducted abroad and in India before granting any emergency authorisation for the vaccine here, official sources said.
Vaccine major Bharat Biotech on Wednesday said its COVID-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials.
Politics, bureaucracy, ineptitude, double-standards and an attempt to politicise the fight in pseudo-nationalistic terms have all hampered the fight against this deadly virus, says Vir Sanghvi.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
India has purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the United States company Novavax and 100 million doses of the Sputnik V candidate from Russia's Gamaleya Research Institute, according to the US-based Duke University Global Health Innovation Center.
The Biden administration had been under pressure to send the excess COVID-19 vaccines with the US to nations like India, which are facing severe vaccine shortages.
Serum Institute of India, the world's largest vaccine manufacturer, has a licence to produce the shot and has already manufactured close to 50 million doses.
The Budget outlay for health and well being is Rs 2.23 lakh crore in 2021-22 as against BE of Rs 94,452 crore and marks an increase of 137 per cent," she said while presenting 2021-22 Budget in the Lok Sabha.
The Union health ministry said in a statement on Monday that over 23,000 adverse events have been reported since the vaccination drive involving Covishield and Covaxin vaccines started in the country and of these 700 cases were reported to be serious.
India has received over USD 20 billion in FDI amid the coronavirus pandemic, Foreign Secretary Harsh Vardhan Shringla said on Tuesday, showcasing the country as one of the most attractive destinations for investment globally.
Of the 4.10 crore to be shared through COVAX, 1.40 crore will go to Latin America and the Caribbean nations and 1.60 crore to Asia.
Dispatch of the vaccine is likely to start by early Tuesday morning, sources said. According to the order placed, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
India's willingness to play a big role in the manufacturing and to allow some of those vaccines to go to other developing countries will be an absolutely critical part of containing the pandemic, said Gates.
Sputnik V is the third vaccine India has given the go-ahead to after 'Covishield', developed by Oxford University and AstraZeneca and 'Covaxin', the indigenous vaccine manufactured by Bharat Biotech. Covishield is manufactured by the Serum Institute of India.
An important focus of the dry run will be on management of any possible adverse events following immunisation.
The data leak obtained by 'The Australian' newspaper has revealed how the alleged CPC members are employed with some of the world's biggest corporations in the areas of defence, banks and pharmaceutical giants manufacturing coronavirus vaccines.
The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances